{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:20:28Z","timestamp":1779250828773,"version":"3.51.4"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Cardiovascular events are one of the main long-term complications in patients with chronic myeloid leukemia (CML) receiving treatment with tyrosine kinase inhibitors (TKIs). The proper choice of TKI and the adequate management of risk factors may reduce cardiovascular comorbidity in this population.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This study evaluated the cardiovascular risk of a cohort of patients with CML at diagnosis and after follow-up in a specialized cardiovascular risk consultation. In order to do this, we performed data analysis from 35 patients who received TKIs and were referred to the aforementioned consultation between 2015 and 2018 at our center. Cardiovascular risk factors were analyzed separately, as well as integrated into the cardiovascular SCORE, both at diagnosis and at the last visit to the specialized consultation.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> At the time of diagnosis, 60% had some type of risk factor, 20% had a high or very high risk SCORE, 40% had an intermediate risk, and 40% belonged to the low risk category. During follow-up, the main cardiovascular adverse event observed was hypertension (diagnosed in 8 patients, 23%). 66% of patients quit smoking, achieving control of blood pressure in 95%, diabetes in 50%, weight in 76%, and dyslipidemia in 92%. 5.7% of patients suffered a thrombotic event and a significant percentage of patients showed a reduction in their SCORE.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our study shows the benefit of controlling cardiovascular risk factors through follow-up in a specialized consultation for patients with CML treated with TKI.<\/jats:p>","DOI":"10.3389\/fphar.2023.1206893","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T07:51:17Z","timestamp":1689753077000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE"],"prefix":"10.3389","volume":"14","author":[{"given":"Alberto","family":"Blanco S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Gil Manso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Carre\u00f1o-Tarragona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Paredes Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Gonz\u00e1lez Olmedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"D\u00edaz Pedroche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"B1","volume-title":"Desk reference to the diagnostic criteria from DSM-5","year":"2013"},{"key":"B2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","volume":"2017","author":"Barber","year":"2017","journal-title":"Hematology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e000057","DOI":"10.1136\/ihj-2020-000057","article-title":"Analysis of the multidisciplinary approach for the management of patients affected by chronic myeloid leukaemia","volume":"4","author":"Basile","year":"2022","journal-title":"Integr. Healthc. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood.2021011722","article-title":"How I treat chronic-phase chronic myelogenous leukemia","volume":"139","author":"Berman","year":"2022","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00277-014-2231-9","article-title":"Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment","volume":"94","author":"Breccia","year":"2015","journal-title":"Ann. Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real\u2010life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.2147\/OTT.S170138","article-title":"Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities","volume":"11","author":"Chaar","year":"2018","journal-title":"OncoTargets Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/onco.13944","article-title":"Tyrosine kinase inhibitors and vascular adverse events in patients with chronic myeloid leukemia: A population-based, propensity score-matched cohort study","volume":"26","author":"Chen","year":"2021","journal-title":"Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"7787","DOI":"10.26355\/eurrev_202112_27625","article-title":"Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence","volume":"25","author":"Ciftciler","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood.2020006911","article-title":"How to manage CML patients with comorbidities","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1182\/asheducation-2016.1.164","article-title":"Chronic myeloid leukemia: Sequencing of TKI therapies","volume":"2016","author":"Cortes","year":"2016","journal-title":"Hematology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.clml.2017.06.011","article-title":"Elevated cardiovascular disease risk in patients with chronic myelogenous leukemia seen in community-based Oncology practices in the United States","volume":"17","author":"Coutinho","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: A population-based cohort study","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: A systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine kinase inhibitors available for chronic myeloid leukemia: Efficacy and safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"561.e1","DOI":"10.1016\/j.medcli.2016.02.022","article-title":"Gesti\u00f3n cardiovascular de los pacientes con leucemia mieloide cr\u00f3nica desde una perspectiva multidisciplinar, y propuesta de protocolo de actuaci\u00f3n por reuni\u00f3n de consenso","volume":"146","author":"Garc\u00eda-Guti\u00e9rrez","year":"2016","journal-title":"Med. Cl\u00ednica"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1016\/S2352-3026(15)00127-1","article-title":"Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: A phase 2 study","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1182\/blood-2021-151538","article-title":"Choice of frontline tyrosine-kinase inhibitor in very elderly patients with chronic myeloid leukemia: A \u201ccampus CML\u201d study","volume":"138","author":"Latagliata","year":"2021","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"674748","DOI":"10.3389\/fphar.2021.674748","article-title":"Arterial hypertension and tyrosine kinase inhibitors in chronic myeloid leukemia: A systematic review and meta-analysis","volume":"12","author":"Mulas","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B27","unstructured":"Chronic myeloid leukemia2023"},{"key":"B28","doi-asserted-by":"publisher","first-page":"107489","DOI":"10.1016\/j.ypmed.2023.107489","article-title":"Peripheral arterial disease (PAD) \u2013 a challenging manifestation of atherosclerosis","volume":"171","author":"Nordanstig","year":"2023","journal-title":"Prev. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s00277-018-3413-7","article-title":"Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?","volume":"97","author":"Osorio","year":"2018","journal-title":"Ann. Hematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11899-019-00546-4","article-title":"Towards a personalized treatment of patients with chronic myeloid leukemia","volume":"14","author":"Rabian","year":"2019","journal-title":"Curr. Hematol. malignancy Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"14637","DOI":"10.1038\/s41598-021-94127-2","article-title":"Arterial hypertension assessment in a population with chronic myeloid leukemia","volume":"11","author":"Roa-Chamorro","year":"2021","journal-title":"Sci. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.htct.2020.04.009","article-title":"Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: Risk assessment, stratification, treatment and monitoring","volume":"43","author":"Seguro","year":"2021","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"671232","DOI":"10.1155\/2015\/671232","article-title":"Clinical experience of patients referred to a multidisciplinary cardiac Oncology clinic: An observational study","volume":"2015","author":"Sulpher","year":"2015","journal-title":"J. Oncol."},{"key":"B35","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines:\u2002The task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1206893\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T07:51:23Z","timestamp":1689753083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1206893\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":38,"alternative-id":["10.3389\/fphar.2023.1206893"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1206893","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"article-number":"1206893"}}